How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Protein Degradation Therapy Market
- By Therapy Type: PROTACs (Proteolysis Targeting Chimeras), Molecular Glues, LYTACs (Lysosome Targeting Chimeras), AUTACs (Autophagy Targeting Chimeras), DUBTACs (Deubiquitinase Targeting Chimeras)
- By Target Protein Class: Kinases, Transcription Factors, Nuclear Receptors, Epigenetic Regulators, E3 Ligases
- By Indication: Oncology, Neurodegenerative Diseases, Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases
- By Drug Development Stage: Preclinical, Clinical Trials Phase I, Clinical Trials Phase II, Clinical Trials Phase III, Approved Drugs
- By Modality: Small Molecule Degraders, Peptide-based Degraders, Antibody-based Degraders
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - PROTACs (Proteolysis Targeting Chimeras) leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 308 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Protein Degradation Therapy Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Target Protein Class 5
Indication 5
Drug Development Stage 5
Modality 3
Companies profiled
Arvinas Inc.
C4 Therapeutics Inc.
Nurix Therapeutics Inc.
Kymera Therapeutics Inc.
Foghorn Therapeutics Inc.
Vividion Therapeutics Inc.
Bristol-Myers Squibb Company
Amgen Inc.
Novartis AG
Pfizer Inc.
Genentech
Inc. (a member of the Roche Group)
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Arvinas Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →C4 Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nurix Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Kymera Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Foghorn Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Vividion Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bristol-Myers Squibb Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Genentech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Inc. (a member of the Roche Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Daiichi Sankyo Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Cerevance Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Monte Rosa Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Almirall
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,107M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- PROTACs (Proteolysis Targeting Chimeras)34.3
- Molecular Glues19.8
- LYTACs (Lysosome Targeting Chimeras)20.4
- AUTACs (Autophagy Targeting Chimeras)13.1
- DUBTACs (Deubiquitinase Targeting Chimeras)12.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$844.6M → $1,249M · 5.0%
Europe$588.7M → $929.3M · 5.9%
Asia Pacific$537.5M → $838.9M · 5.7%
Latin America$332.7M → $573.0M · 7.0%
Middle East and Africa$255.9M → $400.4M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.032026
6.062027
6.062028
6.082029
6.092030
6.102031
6.122032
6.122033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Arvinas Inc.26.6
- C4 Therapeutics Inc.19.2
- Nurix Therapeutics Inc.5.5
- Kymera Therapeutics Inc.5.4
- Foghorn Therapeutics Inc.10.5
- Vividion Therapeutics Inc.5.0
- Others27.8
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type26.4%
Target Protein Class20.9%
Indication16.9%
Drug Development Stage11.1%
Modality24.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe23.3
- Asia Pacific21.0
- Latin America14.4
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Arvinas Inc. | 96 | 89 | 86 | 91 | 74 | 90 | 88 |
| C4 Therapeutics Inc. | 73 | 88 | 84 | 83 | 88 | 91 | 85 |
| Nurix Therapeutics Inc. | 87 | 87 | 80 | 80 | 76 | 74 | 81 |
| Kymera Therapeutics Inc. | 77 | 64 | 75 | 68 | 69 | 68 | 70 |
| Foghorn Therapeutics Inc. | 71 | 72 | 65 | 65 | 59 | 65 | 66 |
| Vividion Therapeutics Inc. | 69 | 68 | 46 | 58 | 53 | 46 | 57 |
| Bristol-Myers Squibb Company | 40 | 60 | 52 | 61 | 51 | 45 | 52 |
| Amgen Inc. | 54 | 56 | 52 | 35 | 60 | 57 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Arvinas Inc.
- C4 Therapeutics Inc.
- Nurix Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Arvinas Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| C4 Therapeutics Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Nurix Therapeutics Inc. | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Kymera Therapeutics Inc. | ◐ | − | ✓ | ✓ | ◐ | ◐ |
| Foghorn Therapeutics Inc. | − | ◐ | − | − | − | ◐ |
| Vividion Therapeutics Inc. | ✓ | ◐ | ◐ | − | ◐ | − |
| Bristol-Myers Squibb Company | − | ◐ | − | ◐ | − | − |
| Amgen Inc. | ◐ | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Arvinas Inc.88
2C4 Therapeutics Inc.85
3Nurix Therapeutics Inc.81
4Kymera Therapeutics Inc.70
5Foghorn Therapeutics Inc.66
6Vividion Therapeutics Inc.57
7Bristol-Myers Squibb Company52
8Amgen Inc.52
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Arvinas Inc.C4 Therapeutics Inc.Nurix Therapeutics Inc.
Challenger1
Strong scale, closing on the leaders.
Kymera Therapeutics Inc.
Contender2
Focused players with pockets of strength.
Foghorn Therapeutics Inc.Vividion Therapeutics Inc.
Niche2
Specialists in a single segment or region.
Bristol-Myers Squibb CompanyAmgen Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Protein Degradation Therapy Market — a $209M beachhead inside a $3.28B market.
Beachhead (SOM)$209Mobtainable near-term
Serviceable (SAM)$1.16Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
PROTACs (Proteolysis Targeting Chimeras)
Best fit — highest urgency & budget in Therapy Type.
Economic buyer81 fit
Molecular Glues
Strong fit — clear ROI and a fast path to value.
End user68 fit
LYTACs (Lysosome Targeting Chimeras)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Protein Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Protein Degradation Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified26%
Evaluation13%
Closed-won7%
$11.6KCAC
$57KLTV
4.9:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Protein Degradation Therapy Market is a durable-growth opportunity — $9.85B by 2033, compounding at 9.9%.
TAM · 2025$4.63Btoday
TAM · 2033$9.85Bforecast
CAGR9.9%2027–2033
Cumulative$62.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.85BTotal addressable market
SAM$3.66BServiceable available market
SOM$667MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.9% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.85BLarge & growingTAM by 2033 at 9.9% CAGR
$3.66BServiceable nowreachable with today’s model
$667MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.68BBear6.4% CAGR
$9.85BBase9.9% CAGR
$12.6BBull13.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Protein Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Protein Degradation Therapy Market — a $5.07B market by 2033. Plan: grow share from 8.3% to 15.0%.
Market size · 2033$5.07Btotal addressable
Market CAGR8.0%2027–2033
Target share15.0%from 8.3% today
Revenue ambition$761Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 15.0% | Behind |
| Revenue | $440M | $761M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.3% | 45.3% | Ahead |
| Customer retention | 86.4% | 94.6% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Protein Class capability
A defensible second engine — invest in Target Protein Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Protein Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Target Protein Class
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Protein Degradation Therapy Market conversation — a $1.17B market you can size, segment and defend in minutes.
Market size · 2033$1.17Btotal opportunity
Growth8.5%CAGR to 2033
Addressable buyers1,224+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 4 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Arvinas Inc.C4 Therapeutics Inc.Nurix Therapeutics Inc.Kymera Therapeutics Inc.Foghorn Therapeutics Inc.Vividion Therapeutics Inc.Bristol-Myers Squibb CompanyAmgen Inc.+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Protein Degradation Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Protein Degradation Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Protein Crosslinker Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportProtein Conjugation Services Market
Protein Conjugation Services Market is valued at USD 840 Million in 2025 and is expected to rea…
$840M market · 2025 base year
View reportProtein Chromatography Resin Market
Market size, share, segmentation and regional forecast.
$679M market · 2025 base year
View reportProtein Chemistry Analyzers Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportProtein Characterization Service Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportProtein C Concentrate Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportProtein-bound Paclitaxel Drug Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportProtein Bound Paclitaxel (Abraxane) Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportProtein Blotting Paper Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportProtein Biological Research Reagents Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportProtein Biological Reagents Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportProtein-based Fluorescent Dye Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.